Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.

@article{Sasse2013BrentuximabV,
  title={Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.},
  author={Stephanie Sasse and Achim Rothe and Helen Goergen and Dennis A. Eichenauer and Andreas Lohri and Stephan Kreher and Ulrich Dr Jaeger and Christopher Bangard and Georg Kuhnert and Boris B{\"o}ll and Bastian von Tresckow and Andreas Engert},
  journal={Leukemia & lymphoma},
  year={2013},
  volume={54 10},
  pages={
          2144-8
        }
}
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients with Hodgkin lymphoma (HL). We thus retrospectively analyzed 14 patients with primary refractory or relapsed HL who were treated with brentuximab vedotin as single agent in a named patient program, who had not received prior high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) due to refractory disease (n = 9), comorbidity (n = 4) and unknown… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 6 EXCERPTS

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2006
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Brentuximab vedotin

  • Nature Reviews Drug Discovery
  • 2012
VIEW 1 EXCERPT

Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies: the GHSG experience

A Rothe, S Sasse, H Goergen
  • Blood
  • 2012
VIEW 2 EXCERPTS